{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:37:49Z","timestamp":1782747469899,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The number of patients with no prostate specific antigen (PSA) decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of\u2009\u2265\u200950% was higher in the E group (p\u2009=\u20090.020). Radiological progression free survival (rPFS) and overall survival (OS) were significantly longer in the E group when compared to that in the AA group (p\u2009&lt;\u20090.001 and p\u2009=\u20090.027, respectively). In the E group, rPFS was significantly longer than that in the AA group in both pre- and post-docetaxel settings (p\u2009=\u20090.010 and p\u2009=\u20090.003, respectively). OS was similar in the pre-docetaxel setting; but in the post-docetaxel setting, E group had a significantly longer OS than the AA group (p\u2009=\u20090.021). In the multivariate analysis performed in the whole patient group, we found that good prognostic factors for rPFS were E treatment, being\u2009\u2265\u200975\u00a0years and a PSA decline of\u2009\u2265\u200950% while there was no factor affecting OS. With longer OS and PFS, E seems to be more suitable for mCRPC patients in the post-docetaxel setting than AA.<\/jats:p>","DOI":"10.1038\/s41598-021-93659-x","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T06:04:40Z","timestamp":1625724280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-7573","authenticated-orcid":false,"given":"Ay\u015fe","family":"Demirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemil","family":"Bilir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"G\u00fclba\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"Hac\u0131bekiro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim V.","family":"Bayo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rem","family":"Bilgetekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Koca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havva Y.","family":"\u00c7\u0131nk\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiye","family":"Akdeniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceyhun","family":"Var\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna","family":"\u00d6ks\u00fczo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"93659_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","volume":"61","author":"MM Center","year":"2012","unstructured":"Center, M. M. et al. International variation in prostate cancer \u0131ncidence and mortality rates. Eur. Urol. 61, 1079\u20131092 (2012).","journal-title":"Eur. Urol."},{"key":"93659_CR2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der, F. H. et al. Screening and prostate-cancer mortality in a randomized european study. N. Engl. J. Med. 360, 1320\u20131328 (2009).","journal-title":"N. Engl. J. Med."},{"key":"93659_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ctrv.2018.11.005","volume":"73","author":"A Dellis","year":"2019","unstructured":"Dellis, A. et al. Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. Cancer Treat Rev. 73, 54\u201361 (2019).","journal-title":"Cancer Treat Rev."},{"key":"93659_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono","year":"2011","unstructured":"Bono, J. S. et al. Abiraterone and \u0131ncreased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"93659_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s40265-013-0129-9","volume":"73","author":"M Sanford","year":"2013","unstructured":"Sanford, M. Enzalutamide: A review of \u0131ts use in metastatic, castration-resistant prostate cancer. Drugs 73, 1723\u20131732 (2013).","journal-title":"Drugs"},{"key":"93659_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.euo.2019.01.008","volume":"3","author":"E Efstathiou","year":"2020","unstructured":"Efstathiou, E. et al. Enzalutamide in combination with abiraterone acetate in bone metastatic castration-resistant prostate cancer patients. Eur. Urol. Oncol. 3, 119\u2013127 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"93659_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.eururo.2019.09.019","volume":"77","author":"AT Vuillemin","year":"2020","unstructured":"Vuillemin, A. T. et al. Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: Final 12-mo analysis from the observational AQUARiUS study. Eur. Urol. 77, 380\u2013387 (2020).","journal-title":"Eur. Urol."},{"key":"93659_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan, C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final Overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16, 152\u2013160 (2015).","journal-title":"Lancet Oncol."},{"key":"93659_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi, K. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 15, 1147\u20131156 (2014).","journal-title":"Lancet Oncol."},{"key":"93659_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","volume":"78","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong, A. J. et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the Preva\u0131l Trial. Eur. Urol. 78, 347\u2013357 (2020).","journal-title":"Eur. Urol."},{"key":"93659_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","volume":"15","author":"S Chowdhury","year":"2020","unstructured":"Chowdhury, S. et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: The prostate cancer registry. Target Oncol. 15, 301\u2013315 (2020).","journal-title":"Target Oncol."},{"key":"93659_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13426","author":"A Oyman","year":"2020","unstructured":"Oyman, A. et al. Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis. Asia Pac. J. Clin. Oncol. https:\/\/doi.org\/10.1111\/ajco.13426 (2020).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"93659_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ctarc.2018.10.001","volume":"17","author":"G Marret","year":"2018","unstructured":"Marret, G., Doucet, L., Hennequin, C., Fizazi, K. & Culine, S. Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. Cancer Treat Res. Commun. 17, 37\u201342 (2018).","journal-title":"Cancer Treat Res. Commun."},{"key":"93659_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-016-0132-z","volume":"16","author":"DMC Poon","year":"2016","unstructured":"Poon, D. M. C. et al. Abiraterone acetate in metastatic castration-resistant prostate cancer\u2014The unanticipated real-world clinical experience. BMC Urol. 16, 1\u201310 (2016).","journal-title":"BMC Urol."},{"key":"93659_CR15","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/pros.22874","volume":"74","author":"R Nadal","year":"2014","unstructured":"Nadal, R. et al. Clinical activity of enzalutamide in docetaxel-na\u00efve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 74, 1560\u20131568 (2014).","journal-title":"Prostate"},{"key":"93659_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11523-020-00759-1","volume":"15","author":"M Fujiwara","year":"2020","unstructured":"Fujiwara, M. et al. Efficacy, prognostic factors, and safety profile of enzalutamide for non-metastatic and metastatic castration-resistant prostate cancer: A retrospective single-center analysis in Japan. Target Oncol. 15, 635\u2013643 (2020).","journal-title":"Target Oncol."},{"key":"93659_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00508-018-1394-0","volume":"130","author":"BM Al-Ali","year":"2018","unstructured":"Al-Ali, B. M., Eredics, K., Madersbacher, S. & Schauer, I. Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer: Adherence, survival and hospitalization analysis of a medical claims database. Wien Klin Wochenschr. 130, 659\u2013664 (2018).","journal-title":"Wien Klin Wochenschr."},{"key":"93659_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.clgc.2016.06.010","volume":"15","author":"H Miyake","year":"2017","unstructured":"Miyake, H., Hara, T., Terakawa, T., Ozono, S. & Fujisawaet, M. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: Experience in real-world clinical practice in Japan. Clin. Genitourin Cancer. 15, 313\u2013319 (2017).","journal-title":"Clin. Genitourin Cancer."},{"key":"93659_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220929414","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. J. Oncol. Pharm. Pract. https:\/\/doi.org\/10.1177\/1078155220929414 (2020).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"93659_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clon.2016.11.020","volume":"29","author":"T Norris","year":"2017","unstructured":"Norris, T., Walter, S., Williams, A., Palmer, J. & McGrane, J. Comparison of toxicity and efficacy outcomes of abiraterone and enzalutamide in 198 patients with metastatic castrate resistant prostate cancer. Clin. Oncol. 29, 87\u201388 (2017).","journal-title":"Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93659-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93659-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93659-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:00:52Z","timestamp":1670047252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93659-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93659"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93659-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-209066\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14131"}}